Committed to Making a Difference
Fundamentals
Profile:
HQ: Cambridge, UK
Incorporated: 1998
Symbol: GWPA, GWPRF
Exchanges: NASDAQ, OTC, London, Germany
CEO: Mr. Justin D. Gover
Focus: Strong
Size:
Market Cap: $4.0 bil
Enterprise Value: $3.8 bil
Size by market cap within cannabis industry: 3rd of 200+
# of employees: 600
Markets: Strong
Primary: USA with new Epidiolex drug
Secondary: Sativex: Outside the USA
Operations: Neutral
Production and Distribution: Neutral
Integration/Diversification: Neutral
Vertically integrated: No. It will produce only, and rely on industry channels to distribute the drug
Horizontally diversified: GW has several drugs in the pipeline, so they are trying to be diversified
Financials: Neutral (no revenue yet from new Epidiolex drug, and costs are still very high.)
Earnings/Revenue/Cost control: $460 mil
Management:
Founder and Exec Chairman: Dr. Geoffrey W. Guy
CEO: Mr. Justin D. Gover
CFO: Scott M. Giacobello
COO: Christopher John Tovey BSc
Branding: Neutral
Valuation: Hold
Financings: Strong (GW has a lot of cash, and does not appear to need to raise money.)
Recommendation: Do not buy (too expensive)